Functional Analysis of the Novel Histone Variant, H2A.J, in Senescence – H2AJFUN
Cellular senescence contributes to organismal aging. In order to identify novel regulators and biomarkers of cellular senescence, we characterized the chromatin of senescent human fibroblasts by a histone profiling method that we developed (Contrepois et al., 2010, 2012). Remarkably, we observed by mass spectrometry the accumulation of a novel H2A variant called H2A.J (Uniprot Q9BTM1) specifically in the chromatin of cells induced into senescence by persistent DNA damage. H2A.J was present at low levels in proliferating or serum-starved fibroblasts. Like H2A.X, H2A.J contains a phosphorylatable C-terminal SQ motif and is expressed constitutively. In a Nature Communications article that was just published (Contrepois et al., 2017), we showed that knock-down of H2A.J does not affect the entry or the maintenance of senescence in response to DNA damage, but does inhibit the expression of inflammatory genes contributing to the Senescence-Associated Secretory Phenotype (SASP).
Scientific Hypotheses: We suggest that H2A.J might represent a novel biomarker for some types of senescent cells in vivo, and that its action might contribute to the expression of a chronic inflammatory phenotype that is implicated in aging-related diseases.
Objectives: For this project, we would like to address the following questions: 1) How does H2A.J accumulation in senescence promote the expression of inflammatory genes? 2) Which cell types express H2A.J in vivo, and is it a useful biomarker for identifying senescent cells in vivo? 3) Does H2A.J have functions that are distinct from senescence, notably with regards to the immune system ? 4) Does H2A.J contribute to chronic inflammation during aging? These last 2 questions will be addressed with our mouse knock-out model.
Project coordination
Carl Mann (Institut de Biologie et de Technologies de Saclay)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partnership
SPI Service de Pharmacologie et d'Immunoanalyse, UMR 0496, Laboratoire d'Etude du Métabolisme des Médicaments, MetaboHUB-Paris, CEA/Saclay
INSERM UMR967- CEA/Fontenay-aux-Roses
UKS Saarland Laboratory of Molecular Radiooncology, Department of Radiotherapy, Saarland University Medical School
KU Kyoto University School of Medicine
IBITEC-S Institut de Biologie et de Technologies de Saclay
Help of the ANR 315,215 euros
Beginning and duration of the scientific project:
September 2017
- 48 Months